New cell therapy aims to stop transplant complications in blood cancer patients

NCT ID NCT04328714

Terminated Disease control Sponsor: Edwin Horwitz Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested whether a special type of cell (interferon gamma-primed mesenchymal stromal cells) could be safely given to prevent graft-versus-host disease, a common and serious complication after bone marrow transplant. Only 4 patients with acute leukemia or myelodysplastic syndrome were enrolled before the study was stopped. The main goals were to see if the cells could be prepared and delivered safely, and to find the best dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia graft versus host disease myelodysplastic syndrome Myelodysplastic Syndromes acute graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Children's Healthcare of Atlanta at Egleston

Atlanta, Georgia, 30322, United States
Emory University

Atlanta, Georgia, 30322, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.